The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer

Mingxiu Ju, Baoyue Pan, Yongwen Huang, Yun Zhou, Jieping Chen, Huiling Xiang, Shije Xu, Siyu Chen, Chunyan Lan, Jundong Li, Min ZhengCancer 2024 · DOI

TL;DR

This study investigates the effectiveness of immunotherapy in patients with recurrent or metastatic cervical cancer (R/M CC), identifying C-reactive protein (CRP) as a key predictor of treatment outcomes. It also highlights that immunotherapy can be effective even after initial failure, with combination therapies showing promise for rechallenged patients.

What Problem Does This Paper Address?

Cervical cancer, despite screening and vaccination efforts, remains a significant global health challenge, particularly in its recurrent or metastatic (R/M) forms. While immunotherapy has revolutionized treatment paradigms, identifying which patients will benefit most remains a challenge. Existing research has explored various prognostic factors, but the role of prior antiangiogenic therapy and the efficacy of subsequent immunotherapy lines in R/M CC patients are less understood. This paper aims to address this gap by retrospectively analyzing a cohort of R/M CC patients treated with immunotherapy, focusing on identifying predictive biomarkers and evaluating treatment strategies after initial immunotherapy failure.

Methods

The researchers conducted a retrospective study involving 208 patients diagnosed with R/M CC who received immunotherapy between August 2018 and September 2022. They collected clinicopathologic information, peripheral blood markers, and treatment data. Key analytical methods included:

  • Response Rate Comparison: Assessing the objective response rate (ORR) and disease control rate (DCR).
  • Univariate and Multivariate Analyses: Using statistical tests (Pearson's chi-square, Kaplan-Meier, Cox proportional hazards regression) to identify factors associated with overall survival (OS) and progression-free survival (PFS).
  • Subgroup Analysis: Examining the efficacy of different treatment regimens, particularly for patients experiencing progression after initial immunotherapy.

The study defined specific cutoffs for various lab values (e.g., CRP >3, GLU >6.1) based on existing literature and clinical guidelines.

Datasets

The study utilized a dataset of 208 R/M CC patients treated at a single institution. This dataset was collected retrospectively and included demographic information, tumor characteristics, treatment history, laboratory values, and survival outcomes. No new benchmarks were introduced; the focus was on analyzing existing patient data.

Key Insights and Ideas

  • CRP as a Prognostic Marker: Baseline serum CRP levels emerged as a significant independent factor predicting both progression-free survival (PFS) and overall survival (OS) in patients treated with immunotherapy. This suggests CRP could be a valuable, readily available biomarker for patient stratification.
  • Antiangiogenic Therapy's Impact: Prior use of antiangiogenic therapy was associated with poorer OS, suggesting a potential resistance mechanism or a marker of more aggressive disease.
  • Immunotherapy Rechallenge is Viable: Patients who progressed on initial immunotherapy can still benefit from subsequent lines of treatment, indicating that immunotherapy rechallenge is a valid strategy.
  • Combination Therapies Shine: For patients undergoing immunotherapy rechallenge, combination therapies, particularly with bevacizumab or dual immunotherapy (anti-PD-1/CTLA-4), demonstrated higher response rates compared to single anti-PD-1 agents.
  • First-Line Immunotherapy Advantage: Patients receiving immunotherapy as a first-line treatment showed a significantly higher objective response rate (ORR) compared to those receiving it in later lines.

Key Results

  • Overall Response: 43.27% of patients achieved an objective response (18 complete responses, 72 partial responses).
  • First-Line vs. Later Lines: First-line immunotherapy yielded a significantly higher ORR (53.8%) compared to subsequent lines (34.8%, p=0.006).
  • Predictive Factors for Survival:
    • Unfavorable OS: CRP >3 and GLU >6.1 independently predicted unfavorable OS.
  • Shorter PFS: CRP >3, ECOG ≥1, and recurrence within 6 months predicted shorter PFS.
  • Antiangiogenic Therapy Impact: Median OS was 34.47 months for patients without prior antiangiogenic therapy versus 20.57 months for those with prior therapy.
  • Rechallenge Efficacy:
    • Chemotherapy + antiangiogenic therapy (C+A) showed a 62.50% ORR.
  • Candonilimab (anti-PD-1/CTLA-4) achieved a 60.00% ORR in patients post-immunotherapy failure, outperforming anti-PD-1 alone (31.58%).
  • Adverse Events: Immunotherapy was generally safe, with anemia and hypothyroidism being the most common adverse events. Serious adverse events leading to discontinuation were rare.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective, Single-Center Design: This design is prone to selection bias and may not be generalizable to broader populations.
  • Lack of Control Group: The study did not include a control group for direct comparison of immunotherapy efficacy against other treatments.
  • Limited Subgroup Analysis: The sample size for immunotherapy rechallenge subgroups was small, necessitating more extensive investigation.
  • Incomplete Data: Genetic testing results (PD-L1 expression, PIK3CA mutation) were not fully collected due to cost, limiting their analysis.

Future work should focus on prospective, multi-center trials to validate these findings. Further research into the mechanisms behind the impact of prior antiangiogenic therapy and the role of specific biomarkers like CRP is warranted. Investigating the optimal sequencing and combination of therapies for immunotherapy rechallenge is also a critical area for future study.

Summary updated

Abstract

The baseline CRP levels in serum was an independent factor for PFS and OS of R/M CC patients treated with immunotherapy, and previous antiangiogenic therapy was associated with poor OS. Patients still show response to immunotherapy rechallenge and combined treatment with bevacizumab or candonilimab showed higher response rate than anti-PD-1 after immunotherapy failure.
BibTeX
@inproceedings{ju2024efficacy,
  author = {Mingxiu Ju and Baoyue Pan and Yongwen Huang and Yun Zhou and Jieping Chen and Huiling Xiang and Shije Xu and Siyu Chen and Chunyan Lan and Jundong Li and Min Zheng},
  title = {{The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer}},
  booktitle = {Cancer},
  year = {2024},
  doi = {10.1002/cam4.70204},
}
Figure